At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 53 enrolled
Drug / intervention
Deferasiroxdrug
Likely dose
Deferasirox 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Multicenter, Single Arm, Phase III Study to Collect Additional Safety and Efficacy Data With Deferasirox Film-coated Tablets in Patients Completing Study CICL670F2201
In Brief
A Phase 3 clinical trial evaluating Deferasirox for Chronic Iron Overload. Completed, enrolled 53 participants across 14 sites in 3 countries.
Detailed Summary
Extend evaluation of deferasirox film-coated tablet (FCT) formulation
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Iron Overload
CountriesAustria, Greece, Italy
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartAug 2016
Primary CompletionJul 2019
TodayJul 2026
First PostedMar 28, 2016
Enrollment StartAug 16, 2016
Primary CompletionJul 23, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.3 years ago
Interventions
Deferasiroxdrug
Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.